Consistent with this, tumor cells carrying p53 dysfunction are usually accompanied with increased expression of PD-L1, which may help to identify patients who respond to immune checkpoint inhibitors against PD-L1 (Cha et al., 2016; Cortez et al., 2016; Biton et al., 2018; Blagih et al., 2020a). This evidence concerns the gene CD274 and neoplasm.